Arbutus Biopharma Corporation
ABUS
$4.58
$0.173.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 191.45M | 14.08M | 14.61M | 15.42M | 6.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 191.45M | 14.08M | 14.61M | 15.42M | 6.40M |
| Cost of Revenue | 20.40M | 25.24M | 29.05M | 37.54M | 47.59M |
| Gross Profit | 171.04M | -11.16M | -14.44M | -22.12M | -41.19M |
| SG&A Expenses | 15.95M | 15.89M | 16.92M | 18.41M | 22.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.35M | 41.13M | 45.96M | 55.95M | 70.22M |
| Operating Income | 155.09M | -27.05M | -31.36M | -40.53M | -63.82M |
| Income Before Tax | 160.72M | -33.50M | -42.28M | -54.25M | -76.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 160.72 | -33.50 | -42.28 | -54.25 | -76.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 160.72M | -33.50M | -42.28M | -54.25M | -76.57M |
| EBIT | 155.09M | -27.05M | -31.36M | -40.53M | -63.82M |
| EBITDA | 155.14M | -26.69M | -30.67M | -39.52M | -62.46M |
| EPS Basic | 0.83 | -0.18 | -0.22 | -0.29 | -0.40 |
| Normalized Basic EPS | 0.51 | -0.08 | -0.09 | -0.12 | -0.19 |
| EPS Diluted | 0.82 | -0.18 | -0.23 | -0.29 | -0.41 |
| Normalized Diluted EPS | 0.51 | -0.08 | -0.09 | -0.12 | -0.19 |
| Average Basic Shares Outstanding | 769.45M | 766.39M | 763.74M | 760.96M | 757.45M |
| Average Diluted Shares Outstanding | 771.75M | 767.24M | 764.59M | 761.81M | 757.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |